Provided herein is a method for preparing an Escitalopram bis-hydroxynaphthoate ((S)-(+)-1-(3+(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-5-cyanisobenzofuranone) crystal form A. Said method is ecofriendly and non pollutive, and the obtained Escitalopram bis-hydroxynaphthoate crystal form A is highly pure and easy to reproduce.

Provided herein is a method for preparing an Escitalopram bis-hydroxynaphthoate ((S)-(+)-1-(3+(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-5-cyanisobenzofuranone) crystal form A. Said method is ecofriendly and non pollutive, and the obtained Escitalopram bis-hydroxynaphthoate crystal form A is highly pure and easy to reproduce.

Provided are a condensed cyclic compound represented by Formula 1 and an organic light-emitting device including the same:

##STR00001##

wherein, in Formula 1, X.sub.1, A.sub.1, L.sub.11, a11, Ar.sub.11, Ar.sub.12, b11, R.sub.11, R.sub.12, c11, and c12 are the same as defined in the specification.

The present disclosure relates to compounds of Formula (I):

##STR00001##

and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.

Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.

Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.

Disclosed are compounds of formula (I): ##STR00001##
and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

Disclosed are compounds of formula (I): ##STR00001##
and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

The present application relates to a polymer containing at least one structural unit of a formula (I). The polymer is suitable for use in an electronic device.

Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.

##STR00001##